BioMark Diagnostics (BUX) Price & Analysis

Compare

3 Followers

BUX Stock Chart & Stats

C$0.46

C$0.00(0.00%)

At close: Dec 24 4:00 PM EST

C$0.46

C$0.00(0.00%)

Day’s Range― - ―

52-Week RangeC$0.20 - C$0.64

Previous CloseN/A

Volume0.00

Average Volume (3M)16.46K

Market Cap

C$65.16M

Enterprise ValueC$65.38M

Total Cash (Recent Filing)C$1.29M

Total Debt (Recent Filing)C$711.78K

Price to Earnings (P/E)―

Beta0.05

Next Earnings

Jul 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding105,090,210

10 Day Avg. Volume19,330

30 Day Avg. Volume16,464

Financial Highlights & Ratios

PEG Ratio0.71

Price to Book (P/B)-41.95

Price to Sales (P/S)156.67

P/FCF Ratio-25.91

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Focused Diagnostics R&DA clear strategy centered on blood-based cancer diagnostics aligns with durable structural demand for earlier, less-invasive detection and ongoing disease monitoring. Clinical validation cycles and biomarker IP can produce long-lived commercial opportunities and higher barriers to entry if assays succeed.

Moderate Reported LeverageOn the latest TTM snapshot debt is modest relative to equity, implying interest and principal obligations are not presently overwhelming. This affords management more runway and optionality to invest in trials or commercialization versus a highly leveraged peer, supporting operational flexibility over months.

Evidence Of Cash Flow ImprovementAn improving free-cash-flow trend, even from a negative base, suggests operating efficiencies or revenue progress. If sustained, that trend reduces near-term financing needs and indicates management can narrow cash burn, improving the firm’s ability to execute clinical and commercialization milestones over the next several months.

Bears Say

Minimal And Declining RevenueRevenue is very small and fell materially year-over-year, indicating weak commercialization traction. Persistently low sales undermine scalability, make covering fixed R&D and SG&A difficult, and extend reliance on financing until assays achieve market adoption or meaningful contract wins.

Material Negative Free Cash FlowSustained negative free cash flow on the order of millions requires repeated external funding, increasing dilution or refinancing risk. Over a multi-month horizon this reduces strategic flexibility, pressures milestone execution, and elevates the probability management must prioritize cash conservation over growth investments.

Deep, Persistent LossesProfitability is severely negative, reflecting high operating costs relative to tiny sales. Continued losses constrain reinvestment, make it harder to achieve scale economics, and extend dependence on capital markets — a structural impediment to becoming self-sustaining within the medium term.

BioMark Diagnostics News

BioMark Wins Peer-Reviewed Validation for AI-Driven Lung Cancer Detection Model

BioMark Diagnostics ( ($TSE:BUX) ) has provided an update. BioMark Diagnostics has achieved a key validation milestone with...

2M ago

BioMark Wins Peer-Reviewed Validation for AI-Driven Lung Cancer Detection Model

BioMark Diagnostics ( ($TSE:BUX) ) has issued an announcement. BioMark Diagnostics has achieved a key validation milestone with...

2M ago

BioMark Leverages Landmark Lung Cancer Studies and New Funding to Drive 2026 Expansion

BioMark Diagnostics ( ($TSE:BUX) ) has issued an announcement. BioMark Diagnostics reported a transformative 2025 marked by major...

3M ago

BioMark Adds AI-Focused Investor James Lavender to Board to Drive U.S. Expansion

BioMark Diagnostics ( ($TSE:BUX) ) has issued an update. BioMark Diagnostics has appointed technology investor and AI-focused growth...

3M ago

BioMark Launches ISO 15189 Accreditation Drive to Accelerate Global Commercialization

An update from BioMark Diagnostics ( ($TSE:BUX) ) is now available. BioMark Diagnostics Inc. has begun the process...

3M ago

BioMark Diagnostics Wins Innovation Award for Lung Cancer Screening Project

BioMark Diagnostics ( ($TSE:BUX) ) has provided an announcement. BioMark Diagnostics Inc. and its research partners have been...

4M ago

BioMark Supports National Plan to Slash Lung Cancer Mortality

BioMark Diagnostics ( ($TSE:BUX) ) has provided an update. BioMark Diagnostics Inc. is aligning with the Canadian Cancer...

4M ago

BioMark Joins Landmark German Lung Cancer Screening Trial

The latest announcement is out from BioMark Diagnostics ( ($TSE:BUX) ). BioMark Diagnostics Inc. has been selected to...

5M ago

BioMark Secures Patents in China and Japan for Lung Cancer Detection

BioMark Diagnostics ( ($TSE:BUX) ) has provided an update. BioMark Diagnostics Inc. has secured key patents in China...

6M ago

BioMark Diagnostics Expands into North Africa with Strategic Partnership

BioMark Diagnostics ( ($TSE:BUX) ) just unveiled an announcement. BioMark Diagnostics has announced a strategic partnership with SAMA...

7M ago

BUX FAQ

What was BioMark Diagnostics’s price range in the past 12 months?

BioMark Diagnostics lowest stock price was C$0.20 and its highest was C$0.64 in the past 12 months.

What is BioMark Diagnostics’s market cap?

BioMark Diagnostics’s market cap is C$65.16M.

When is BioMark Diagnostics’s upcoming earnings report date?

BioMark Diagnostics’s upcoming earnings report date is Jul 15, 2026 which is in 121 days.

How were BioMark Diagnostics’s earnings last quarter?

BioMark Diagnostics released its earnings results on Mar 02, 2026. The company reported -C$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.004.

Is BioMark Diagnostics overvalued?

According to Wall Street analysts BioMark Diagnostics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does BioMark Diagnostics pay dividends?

BioMark Diagnostics does not currently pay dividends.

What is BioMark Diagnostics’s EPS estimate?

BioMark Diagnostics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does BioMark Diagnostics have?

BioMark Diagnostics has 105,090,210 shares outstanding.

What happened to BioMark Diagnostics’s price movement after its last earnings report?

BioMark Diagnostics reported an EPS of -C$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of BioMark Diagnostics?

Currently, no hedge funds are holding shares in TSE:BUX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

BioMark Diagnostics

BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.